Business
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Oakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. ( NASDAQ:...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare ConferenceOakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, at 8:40 am EDT.A live audio webcast will be available on the \"Events & Presentations\" section of Cardiol's website at cardiolrx.com/investors/events-presentations/. A replay of the presentation will be available for approximately 90 days.About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (\"CVD\"). The Company's lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase II/III outcomes study (the LANCER trial). The LANCER trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.Cardiol has also received clearance from the FDA for its investigational new drug (\"IND\") application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure - a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.For more information about Cardiol Therapeutics, please visit cardiolrx.com.Cautionary statement regarding forward-looking information:This news release contains \"forward-looking...